Benchmark reduced its price target and set a buy rating for Abbott Laboratories, while Royal Bank of Canada issued an outperform rating on July 29, 2026.
4 reports, 1 independent
Updated Oct 25
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Benchmark reduced its price target and set a buy rating for Abbott Laboratories, while Royal Bank of Canada issued an outperform rating on July 29, 2026.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Bank of America lowered its price target for Abbott stock.1 source
Benchmark reduced price target and set buy rating for Abbott Laboratories; RBC issued outperform rating.1 source
Keep exploring
The entities involved
-
Abbott Laboratories
American global health care and medical device products company
-
Benchmark
venture capital firm
-
Royal Bank of Canada
financial institution in Canada
Related events
- Royal Bank of Canada issued an outperform rating, and Truist Financial increased its target price and gave buy rating for CubeSmart.
- Royal Bank of Canada boosted its price objective for Seabridge Gold, with MarketBeat providing consensus rating data.
- Financial firms including Truist, RBC, TD Cowen, and Jefferies issued various rating updates on October 30, 2026.
- Royal Bank of Canada, Citigroup, and Morgan Stanley issued price target and rating updates on August 27, 2026.
- Royal Bank of Canada lifted its price objective for Automotive Properties REIT, with MarketBeat providing average rating data.